[go: up one dir, main page]

MX2018000745A - Metodos para tratar trastornos del desarrollo con gaboxadol. - Google Patents

Metodos para tratar trastornos del desarrollo con gaboxadol.

Info

Publication number
MX2018000745A
MX2018000745A MX2018000745A MX2018000745A MX2018000745A MX 2018000745 A MX2018000745 A MX 2018000745A MX 2018000745 A MX2018000745 A MX 2018000745A MX 2018000745 A MX2018000745 A MX 2018000745A MX 2018000745 A MX2018000745 A MX 2018000745A
Authority
MX
Mexico
Prior art keywords
syndrome
methods
gaboxadol
disorder
developmental disorders
Prior art date
Application number
MX2018000745A
Other languages
English (en)
Other versions
MX391708B (es
Inventor
During Matthew
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of MX2018000745A publication Critical patent/MX2018000745A/es
Publication of MX391708B publication Critical patent/MX391708B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se proporcionan métodos para tratar trastornos del desarrollo tales como síndrome de Angelman, síndrome X frágil, síndrome de temblor/ataxia asociado a X frágil (FXTAS), trastorno de espectro autista, autismo, síndrome de Asperger, trastorno generalizado del desarrollo, trastorno desintegrativo infantil, síndrome de Rett, síndrome de Lanau-Kleffner, síndrome de Prader-Willi, discinesia tardía y/o síndrome de Williams con gaboxadol o una sal farmacéuticamente aceptable de la misma. Los métodos proporcionan composiciones terapéuticas que pueden usarse para mejorar uno o más síntomas del trastorno del desarrollo.
MX2018000745A 2015-07-17 2016-07-14 Metodos para tratar trastornos del desarrollo con gaboxadol. MX391708B (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562193717P 2015-07-17 2015-07-17
US201562207595P 2015-08-20 2015-08-20
US201662332567P 2016-05-06 2016-05-06
US201662346763P 2016-06-07 2016-06-07
US15/209,862 US20170014393A1 (en) 2015-07-17 2016-07-14 Methods of treating developmental disorders with gaboxadol
PCT/US2016/042238 WO2017015049A1 (en) 2015-07-17 2016-07-14 Methods of treating developmental disorders with gaboxadol

Publications (2)

Publication Number Publication Date
MX2018000745A true MX2018000745A (es) 2018-08-15
MX391708B MX391708B (es) 2025-03-21

Family

ID=57774846

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018000745A MX391708B (es) 2015-07-17 2016-07-14 Metodos para tratar trastornos del desarrollo con gaboxadol.
MX2022004734A MX2022004734A (es) 2015-07-17 2018-01-17 Metodos para tratar trastornos del desarrollo con gaboxadol.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022004734A MX2022004734A (es) 2015-07-17 2018-01-17 Metodos para tratar trastornos del desarrollo con gaboxadol.

Country Status (17)

Country Link
US (8) US20170014393A1 (es)
EP (2) EP3324961B1 (es)
JP (3) JP2018520189A (es)
KR (2) KR20180031721A (es)
CN (2) CN108024997A (es)
AU (2) AU2016295138B2 (es)
BR (1) BR112018000933A2 (es)
CA (1) CA2992734A1 (es)
CL (1) CL2018000142A1 (es)
CO (1) CO2018000375A2 (es)
ES (1) ES3021189T3 (es)
HK (1) HK1250951A1 (es)
IL (2) IL256912B2 (es)
MX (2) MX391708B (es)
PE (2) PE20230735A1 (es)
TW (2) TWI819995B (es)
WO (1) WO2017015049A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3372229T1 (sl) 2014-06-06 2021-09-30 Ovid Therapeutics, Inc. Postopki za povečanje tonične inhibicije in zdravljenje angelman sindroma
KR20180031721A (ko) 2015-07-17 2018-03-28 오비드 테라퓨틱스 인크. 가복사돌로 발달장애들을 치료하는 방법들
WO2018031748A1 (en) 2016-08-11 2018-02-15 Ovid Therapeutics Inc. Methods and compositions for treatment of epileptic disorders
JP2019535760A (ja) * 2016-11-22 2019-12-12 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． フルピルチンを用いた発達障害および／または発作性障害の処置方法
US10071083B2 (en) * 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
US20180338959A1 (en) * 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
US10813918B2 (en) 2017-08-04 2020-10-27 Ovid Therapeutics Inc. Use of Gaboxadol in the treatment of diabetes and related conditions
MX2020004974A (es) * 2017-11-14 2020-08-24 Sk Biopharmaceuticals Co Ltd Uso del compuesto de carbamato para reducir o tratar trastornos del desarrollo que incluyen sindrome x fragil, sindrome de angelman o sindrome de rett.
CA3103267A1 (en) * 2018-06-14 2019-12-19 Ovid Therapeutics Inc. Use of mir-92a or mir-145 in the treatment of angelman syndrome
AU2019326539A1 (en) * 2018-08-22 2021-03-11 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of gastrointestinal tract disorders and asthma
KR20210062662A (ko) 2018-09-20 2021-05-31 오비드 테라퓨틱스 인크. 투렛 증후군, 틱들 및 말더듬의 치료를 위한 가복사돌의 사용
CN114072154B (zh) * 2018-11-21 2024-03-08 塞迪戈Abc有限责任公司 用于治疗精神障碍的加波沙朵和锂的组合物
AU2019384157A1 (en) 2018-11-21 2021-06-17 Certego Therapeutics Inc. Gaboxadol for reducing risk of suicide and rapid relief of depression
KR20210105387A (ko) 2018-12-17 2021-08-26 오비드 테라퓨틱스 인크. 비-24 시간 수면-각성 장애의 치료를 위한 가복사돌의 사용
CN114340597B (zh) * 2019-06-07 2025-01-28 帕克斯医学有限公司 用于治疗中枢神经系统障碍的组合物和方法
EP3982937A4 (en) * 2019-07-15 2022-08-10 Ovid Therapeutics Inc. PHARMACEUTICAL FORMULATIONS WITH GABOXADOL FOR THERAPEUTIC TREATMENT
WO2021127308A1 (en) * 2019-12-18 2021-06-24 Ovid Therapeutics Inc. GABOXADOL FOR THERAPEUTIC TREATMENT OF 1p36 DELETION SYNDROME
WO2021236876A2 (en) 2020-05-20 2021-11-25 Certego Therapeutics Inc. Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2830083A (en) 1953-04-29 1958-04-08 Allied Chem & Dye Corp Production of aryloxy aliphatic carboxylic acids
US4084000A (en) 1975-07-16 1978-04-11 Nelson Research And Development Company Method of treating schizophrenia
US4138484A (en) 1976-08-16 1979-02-06 Nelson Research & Development Company Method for treating schizophrenia and method and composition for potentiating neuroleptic drugs
US4129652A (en) 1976-08-16 1978-12-12 Nelson Research & Development Company Method for potentiating neuroleptic drugs
DK270278A (da) 1977-06-20 1978-12-21 Krogsgaard Larsen P Cycliske aminosyrer
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4353910A (en) 1981-11-27 1982-10-12 Kefalas A/S Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment
JPS61277618A (ja) 1985-06-04 1986-12-08 Suntory Ltd 自閉症治療剤
DE19525598C2 (de) 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
DE19526864A1 (de) 1995-07-22 1997-01-23 Labtec Gmbh Hormonpflaster
US6461644B1 (en) 1996-03-25 2002-10-08 Richard R. Jackson Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
AR031473A1 (es) 2000-11-20 2003-09-24 Lundbeck & Co As H Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide
US20020082222A1 (en) * 2000-11-30 2002-06-27 Shapira Nathan Andrew Treatments for neurogenetic disorders, impulse control disorder, and wound healing
US20020165217A1 (en) 2001-05-01 2002-11-07 Pfizer Inc. Combination treatment for anxiety and depression
EA009731B1 (ru) 2001-05-21 2008-02-28 Х.Лундбекк А/С Гранулярные препараты габоксадола
US6676961B1 (en) 2002-03-06 2004-01-13 Automated Carrier Technologies, Inc. Transdermal patch assembly
US20050234093A1 (en) 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
DK1641456T3 (da) 2003-06-25 2010-06-21 Lundbeck & Co As H Gaboxadol til behandling af depression og andre affektive lidelser
EP1663218A1 (en) 2003-09-10 2006-06-07 MERCK SHARP & DOHME LTD. Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome
US20050137222A1 (en) * 2003-12-18 2005-06-23 H. Lundbeck A/S Treatment of insomnia in human patients
TW200528098A (en) 2003-12-18 2005-09-01 Lundbeck & Co As H Treatment of insomnia in human patients
WO2005063248A1 (en) 2003-12-22 2005-07-14 Sepracor Inc. Modafinil combination therapy for improving sleep quality
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
JP2007530604A (ja) 2004-04-02 2007-11-01 ハー・ルンドベック・アクチエゼルスカベット 呼吸機能障害の治療
CN1942185A (zh) * 2004-04-02 2007-04-04 H.隆德贝克有限公司 用加波沙朵治疗呼吸功能损伤
GB0417558D0 (en) * 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
DE102005020882A1 (de) 2005-05-04 2006-11-09 Dömling, Alexander, Dr. Verwendung von Gaboxadol und Derivaten zur Behandlung von Kinase-induzierten Krankheiten
US20110046090A1 (en) 2005-10-31 2011-02-24 Braincells Inc. Modulation of neurogenesis with gaba agents and gaba analogs
EP2314289A1 (en) * 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
EP2083811B1 (en) * 2006-11-22 2016-10-26 Clinical Research Associates, LLC Methods of treating down's syndrome, fragile x syndrome and autism
AU2007346591A1 (en) 2007-02-07 2008-08-14 Gosforth Centre (Holdings) Pty Ltd Treatment of ADHD
US20090269795A1 (en) 2007-03-09 2009-10-29 The Research Foundation Of State University Of New York Mutant alpha4betadelta GABAA receptor and methods of treating anxiety or irritability
TW200920358A (en) 2007-08-13 2009-05-16 Lundbeck & Co As H Method of treating stress-mediated depression
US20090048288A1 (en) 2007-08-13 2009-02-19 H. Lundbeck A/S Method of treating stress-mediated depression
US20090143335A1 (en) * 2007-10-29 2009-06-04 H. Lundbeck A/S Modified absorption formulation of gaboxadol
EP2334299A1 (en) 2008-09-01 2011-06-22 H. Lundbeck A/S Pharmaceutical composition comprising gaboxadol and an inhibitor of patl or oat
US20100286762A1 (en) 2009-03-18 2010-11-11 Musc Foundation For Research Development Compositions and Methods for Ameliorating Clinical Electrical Disturbances
CN102147667A (zh) 2010-02-08 2011-08-10 深圳富泰宏精密工业有限公司 触控笔
CN107050456B (zh) 2010-09-28 2022-08-12 加利福尼亚大学董事会 治疗代谢综合征相关疾病的gaba激动剂和治疗或预防i型糖尿病的gaba组合
WO2012075286A2 (en) 2010-12-01 2012-06-07 The Regents Of The University Of California Intrapulmonary benzodiazepine for the treatment and prevention of seizures
US9480695B2 (en) 2011-09-29 2016-11-01 The University Of Tokyo Methods for inducing orexin neurons and agent for treating narcolepsy or eating disorder
EP2765989B1 (en) 2011-10-13 2016-04-13 Jaleva Pharmaceuticals LLC Methods and compositions for rapid transbuccal delivery of active agents
AU2013352141B2 (en) * 2012-11-30 2018-04-05 The Regents Of The University Of California Anticonvulsant activity of steroids
WO2014123909A1 (en) 2013-02-05 2014-08-14 University Of Washington Through Its Center For Commercialization Positive allosteric modulators of the gaba-a receptor in the treatment of autism
SI3372229T1 (sl) * 2014-06-06 2021-09-30 Ovid Therapeutics, Inc. Postopki za povečanje tonične inhibicije in zdravljenje angelman sindroma
ES2664810T3 (es) 2014-06-12 2018-04-23 Pfizer Limited Derivados de imidazopiridazina como moduladores de la actividad del receptor GABAA
US20170348232A1 (en) 2016-06-07 2017-12-07 Ovid Therapeutics Inc. Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome
KR20180031721A (ko) 2015-07-17 2018-03-28 오비드 테라퓨틱스 인크. 가복사돌로 발달장애들을 치료하는 방법들
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
US9399034B1 (en) 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment
JP6857647B2 (ja) 2015-08-11 2021-04-14 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． クリティカル・ケア処置中に用いるための鎮静方法および非経腸製剤
US9351968B1 (en) 2015-09-09 2016-05-31 Ovid Therapeutics Inc Methods of treating developmental disorders using pipradrol
FI3364993T3 (fi) 2015-10-22 2023-01-13 Menetelmiä angelmanin oireyhtymän hoitamiseksi
WO2017205606A1 (en) 2016-05-26 2017-11-30 Ovid Therapeutics Inc. Methods of treating behavioral syndromes using pipradrol
WO2018031748A1 (en) 2016-08-11 2018-02-15 Ovid Therapeutics Inc. Methods and compositions for treatment of epileptic disorders
JP2019535760A (ja) 2016-11-22 2019-12-12 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． フルピルチンを用いた発達障害および／または発作性障害の処置方法
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus

Also Published As

Publication number Publication date
US20190321342A1 (en) 2019-10-24
CN108024997A (zh) 2018-05-11
IL256912A (en) 2018-03-29
US20170014393A1 (en) 2017-01-19
PE20190338A1 (es) 2019-03-07
TW202325293A (zh) 2023-07-01
JP2018520189A (ja) 2018-07-26
EP3324961A4 (en) 2019-03-13
EP3324961C0 (en) 2025-03-19
KR20180031721A (ko) 2018-03-28
WO2017015049A1 (en) 2017-01-26
MX2022004734A (es) 2022-05-13
US20190117632A1 (en) 2019-04-25
US11096929B2 (en) 2021-08-24
CO2018000375A2 (es) 2018-04-19
US12465597B2 (en) 2025-11-11
CN116531370A (zh) 2023-08-04
PE20230735A1 (es) 2023-05-03
TWI819995B (zh) 2023-11-01
TW201707700A (zh) 2017-03-01
US20230071127A1 (en) 2023-03-09
HK1250951A1 (zh) 2019-01-18
ES3021189T3 (en) 2025-05-26
BR112018000933A2 (pt) 2018-09-04
EP3324961B1 (en) 2025-03-19
IL305342A (en) 2023-10-01
EP4541420A3 (en) 2025-06-25
IL256912B2 (en) 2024-01-01
AU2021250862A1 (en) 2021-11-04
EP3324961A1 (en) 2018-05-30
US20210030727A1 (en) 2021-02-04
CA2992734A1 (en) 2017-01-26
MX391708B (es) 2025-03-21
US20180098974A1 (en) 2018-04-12
KR20240160666A (ko) 2024-11-11
EP4541420A2 (en) 2025-04-23
IL256912B1 (en) 2023-09-01
AU2021250862B2 (en) 2023-11-09
US20190255027A1 (en) 2019-08-22
JP2021130687A (ja) 2021-09-09
JP2023103375A (ja) 2023-07-26
AU2016295138A1 (en) 2018-02-08
US20180338960A1 (en) 2018-11-29
CL2018000142A1 (es) 2018-07-13
AU2016295138B2 (en) 2021-11-04

Similar Documents

Publication Publication Date Title
MX2018000745A (es) Metodos para tratar trastornos del desarrollo con gaboxadol.
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
MX385876B (es) Composicion farmaceutica que comprende lenalidomida amorfa y un antioxidante.
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
MX2018008052A (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
CL2018002334A1 (es) Moduladores de complementos factor b (divisional solicitud 201600606)
MX2018005829A (es) Composiciones para tratar el cabello.
CO2018002598A2 (es) Compuestos para modular la expresión de angiotensinógeno, composiciones que los contienen y procesos para su producción
ECSP17010156A (es) Compuestos aminopirimidinilo como inhibidores jak
UY35971A (es) Macrociclos con grupos p2? aromáticos como inhibidores del factor xia
CL2016001706A1 (es) Compuestos de nicotinamida sustituida con heteroarilo
MX2018006578A (es) Formulaciones farmaceuticas topicas para tratar afecciones inflamatorias.
CR20160564A (es) Dinucleótidos cíclicos como moduladores de sting
MX2016009428A (es) Proteinas de union a calicreina en plasma y usos de las mismas para tratar el angioedema hereditario.
DK3313838T3 (da) Polycykliske amidderivater som cdk9-inhibitorer
CR20160528A (es) Compuestos y composiciones para inducir condrogénesis
EA201592106A2 (ru) Локальное сопутствующее введение толерогенных синтетических наноносителей для снижения гиперчувствительности типа i и гиперчувствительности типа iv
MX2017015990A (es) Composiciones topicas que comprenden un corticosteroide y un retinoide para tratar psoriasis.
UY36287A (es) COMPUESTO DE OBJETIVO A IL-23A y TNF-ALFA Y USO DEL MISMO
MX370900B (es) Derivados del isocromeno como inhibidores de las fosfoinositido-3 cinasas.
CL2016000726A1 (es) Derivados de 4-azaindol
DOP2016000073A (es) Composiciones y métodos para inhibir la expresión del gen alas1
MX2017016149A (es) Compuestos triciclicos y su uso como inhibidores de la fosfodiesterasa.
AU2014207408A8 (en) Pharmaceutical compositions comprising nitroxyl donors
DOP2017000058A (es) Derivados de tetrahidroquinolina como inhibidores del bromodominio